Polymorphism is the existence of a chemical in two or more crystalline phases with different molecular packing or conformation. Those small structural differences can change melting point, solubility, dissolution, particle habit, stability, compressibility, filterability, flow, hardness, density, hygroscopicity, color, drug-product appearance, and process robustness.
A polymorph screen is not simply a search for forms. It is a risk-control experiment designed to determine whether the material used for PK, tox, formulation, stability, scale-up, or release is representative and controllable.
Energy differences between forms are usually small. Interconversion can occur during routine API manufacturing, formulation, milling, granulation, compression, storage, or use. A form that looked stable at small scale can be displaced by a more stable form when time, humidity, solvent history, mechanical stress, or seed exposure changes.
A decision-quality screen therefore keeps the material history attached to every sample: solvent, isolation method, drying condition, stress exposure, age, and analytical method. Without that context, a form list can be misleading because the same XRPD pattern may represent a stable target form, a kinetic product, a desolvated hydrate, or a processing artifact.
Triclinic can design preliminary, extensive, or limited-material polymorph screens. A preliminary screen focuses on risk and likely stable forms. An extensive screen supports IP, regulatory confidence, and lifecycle coverage. A limited-material screen can be used when sample availability is below one gram.
The variety of generation conditions is more important than the raw number of experiments. Solvent-based crystallization, slurry competition, thermal methods, grinding and solvent-drop experiments, sonication, vapor, pressure, hot-stage/Kofler methods, and novel nucleation conditions are selected according to the compound and the development question.
| Development point | Minimum solid-state action | Decision-quality output |
|---|---|---|
| Early discovery / lead optimization | Confirm crystallinity and form on key lots; compare lots with unusual solubility, dissolution, or exposure. | Risk flag: representative, metastable, amorphous, mixed, hydrated, solvated, or unknown. |
| Candidate selection | Run targeted polymorph, hydrate, solvate, salt/cocrystal, and ASD feasibility work; begin thermodynamic ranking. | Preferred developable form, fallback path, and known hydrate, solvate, salt, cocrystal, or ASD risks. |
| Preclinical tox / Phase I | Lock a form-control strategy; stress material against humidity, vehicle, slurry, milling, compression, and storage. | Reproducible cGMP form, process sensitivity statement, and method that confirms intended form. |
| Phase II/III / commercial | Complete broader screening; qualify release and stability methods; control process transfer, seeding, packaging, and lifecycle risks. | Control strategy linking form, process, specs, stability, packaging, site transfer, and lifecycle/IP decisions. |
Early discovery frequently samples kinetic products because rapid precipitation, evaporation, short aging, and limited material favor accessible forms. Development pressure changes the experiment: time, scale, humidity, thermal excursions, solvents, excipients, mechanical stress, and seeding can overcome kinetic barriers.
Monotropic systems have one thermodynamic winner across the relevant temperature range. Enantiotropic systems switch the thermodynamic winner at a transition temperature below melting. The relationship should not be inferred from melting point alone; use DSC, slurry conversion, temperature-dependent solubility, van't Hoff analysis, or other thermodynamic evidence.
The practical question is not just which form is lowest in free energy under one laboratory condition. It is whether the selected form will remain the controlled form under the program's process, packaging, storage, formulation, and analytical conditions.
Polymorph screening should be scoped to the decision gate. A candidate-selection screen, a cGMP form-control screen, a prior-art reproduction project, and a lifecycle/IP search should not be the same package.
Triclinic prioritizes diversity of generation conditions, careful interpretation, retained-sample comparisons, and orthogonal confirmation over simple experiment count. The output should state what forms are known, how they interconvert, which form is preferred, what risks remain, and how the form should be monitored.
Use this decision tree to connect form selection, form control, formulation, process development, method development, release testing, stability, and lifecycle risk before the examples and publications section.
Polymorph work should deliberately sample both kinetic and thermodynamic space. Supersaturation, solvent functionality, polarity, hydrogen bonding, water mixtures, temperature, aging time, mechanical stress, and seed exposure can all influence which form appears.
High-throughput experiment count can create false confidence if the screen repeatedly samples the same accessible pathway. A useful polymorph screen is judged by whether it explores the pathways relevant to the molecule, process, dosage form, and IP objective, then scales and characterizes unique forms before property comparisons.
| Decision signal | What to test | Actionable output |
|---|---|---|
| Kinetic forms | Rapid precipitation, antisolvent addition, grinding, melt crystallization, and stress conditions can reveal forms that matter during processing. | Use the findings to flag process sensitivity and disappearing-form risk. |
| Thermodynamic ranking | Slurry aging, competitive experiments, temperature-dependent solubility, and water-activity boundaries identify stable forms and reversals. | Use ranking to support long-term form selection and control. |
| CSP support | Computational crystal structure prediction can guide the search, but energy gaps, solvent effects, flexibility, and kinetic accessibility limit it. | Treat CSP as a guide, not final evidence of accessible forms. |
Variable-temperature and variable-relative-humidity PXRD is useful when polymorph, hydrate, or phase-transition behavior depends on the temperature/RH space that the API will experience in storage or processing.
Screen ionizable APIs for counterions that improve crystallinity, solubility, dissolution, stability, manufacturability, or developability while controlling disproportionation risk.
View serviceUse coformer selection, phase-diagram logic, crystallization methods, and formulation strategy to improve properties and expand solid-form options.
View serviceCharacterize non-crystalline materials, local order, recrystallization risk, spray drying feasibility, polymer selection, drug loading, and solid-dispersion stability.
View serviceBuild reproducible crystallization processes that control the chosen solid form, particle attributes, purity, and scale-up behavior.
View serviceResolve form conversion, failed crystallizations, process sensitivity, stability drift, unexplained PK/dissolution changes, and batch-to-batch material differences.
View serviceBegin before toxicology or clinical commitments when possible, then increase rigor as the program approaches cGMP supply, pivotal studies, commercial transfer, or lifecycle and IP decisions.
Quality depends on the diversity and relevance of the conditions, not the raw experiment count. A strong screen explores solvent history, water activity, temperature, slurry competition, mechanical stress, seeding, isolation, and storage conditions that matter to the molecule and development stage, then follows unexpected behavior with scientist-directed experiments.
No. A screen defines the forms found under the conditions studied and reduces uncertainty; it cannot prove that an undiscovered form will never appear. The output should state residual risk and the control strategy appropriate to the development stage.
Different crystal structures have different lattice stability and may therefore show different solubility and dissolution behavior. The observed result also depends on particle size, morphology, wetting, formulation, dose, permeability, precipitation, and transformation during testing. A polymorphic difference does not automatically produce a clinically meaningful difference in bioavailability.
Confidence requires a reproducible, distinct crystalline phase and exclusion of hydrates, solvates, salts, cocrystals, amorphous material, degradation products, and mixtures. XRPD is primary because it directly probes long-range crystalline order, but thermal analysis, spectroscopy, microscopy, water or solvent measurements, and structural methods may be needed for complete classification.
The key output is a preferred form or risk statement, the known alternative forms, evidence about relative stability and process sensitivity, and a monitoring or control recommendation appropriate to the next development gate.
The form should be confirmed, classified, and assessed in proportion to risk. The critical questions are whether it is reproducible, whether it can occur in the proposed manufacturing process or drug product, and whether it affects stability, manufacturability, dissolution, exposure, analytical control, or intellectual property. Discovery does not automatically require reformulation or routine specification.
Solvent exposure, water activity, temperature, drying, pressure, shear, milling, granulation, compression, excipients, and seeding can favor another phase. Conversion may occur through solid-state rearrangement, solution-mediated recrystallization, dehydration, desolvation, or an amorphous intermediate. Risk should be evaluated at relevant unit operations, not only in the incoming API and final product.
Send the polymorph question, material history, screening data, known forms, process and storage stresses, formulation context, and decision timeline. Triclinic can help determine which solid-form evidence is relevant to the project, whether additional screening or thermodynamic ranking is needed, and how the selected form should be monitored through development.
